Pharmaceutical composition for amelioration of lower urinary tract symptom associated with prostatomegaly

Abstract

Disclosed is a pharmaceutical composition comprising (R)-5-(2-¢¢2-(2-ethoxyphenoxy)ethyl!amino!propyl)-2-methoxybenzene-1-sulfonamide (tamsulosin) or a pharmaceutically acceptable salt thereof and (1S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate (3R)-quinuclidin-3-yl ester (solifenacin) or a pharmaceutically acceptable salt thereof as active ingredients, particularly a pharmaceutical composition for ameliorating a lower urinary tract symptom associated with prostatomegaly. Also disclosed is use of a combination of tamsulosin or a pharmaceutically acceptable salt thereof and solifenacin or a pharmaceutically acceptable salt thereof for the amelioration of a lower urinary tract symptom associated with prostatomegaly. Further disclosed is a combination therapy.

Description

technical field [0001] The present invention relates to a medicine, in particular to a pharmaceutical composition for improving lower urinary tract symptoms accompanied by prostatic hypertrophy, especially containing (R)-5-(2-{[2-(2-ethoxyphenoxy Base) ethyl] amino} propyl) -2-methoxybenzene-1-sulfonamide (hereinafter referred to as tamsulosin (tamsulosin)) or its pharmaceutically acceptable salt, and (1S)-1-benzene Base-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid (3R)-quinuclidin-3-yl ester (hereinafter referred to as solifenacin (solifenacin)) or its pharmaceutically acceptable Pharmaceutical composition with salt as active ingredient. The present invention also relates to the combined use of tamsulosin or a pharmaceutically acceptable salt thereof and solifenacin or a pharmaceutically acceptable salt thereof for improving lower urinary tract symptoms accompanied by prostatic hypertrophy, and a combined treatment method. Background technique [0002] The prostate is...

AI Technical Summary

Problems solved by technology

However, the literature does not report its improvement effect on voiding symptoms

Images